Management of Insomnia in Patients with Complex Polypharmacy

Guideline Recommendations

The VA/DOD Clinical Practice Guidelines explicitly suggest against the use of trazodone for chronic insomnia disorder (weak recommendation) 1
The American Academy of Sleep Medicine recommends against using trazodone for both sleep onset and sleep maintenance insomnia, rating this as a "WEAK" recommendation based on low-quality evidence 2, 3
Clinical trials of trazodone 50 mg showed only modest improvements in sleep parameters compared to placebo, with no significant improvement in subjective sleep quality 2
The benefits of trazodone for sleep do not outweigh the potential harms according to guideline assessments 2
The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the initial treatment for chronic insomnia, even in patients with comorbid psychiatric disorders 1, 2, 3
CBT-I is recommended over pharmacotherapy as first-line treatment (weak recommendation) 1

Low-dose doxepin (3-6 mg) is recommended for sleep maintenance insomnia - this is specifically recommended by guidelines for short-course pharmacotherapy 1, 2, 3
Non-benzodiazepine BZRAs (zolpidem 10 mg, eszopiclone 2-3 mg, zaleplon 10 mg) are preferred over trazodone 2, 3
Ramelteon 8 mg is recommended for sleep onset insomnia 2, 3
Suvorexant is recommended for sleep maintenance insomnia 2, 3

The American Academy of Sleep Medicine specifically warns against combining two sedating antidepressants due to risks of serotonin syndrome, excessive sedation, and QT prolongation 3
Guidelines recommend against benzodiazepines (weak recommendation), yet this patient is already on alprazolam PRN 1
Diphenhydramine, melatonin, valerian, and chamomile are all recommended against for chronic insomnia 1, 2, 3